ASML set to report decline in profits and sales for Q1 amid semiconductor industry challenges – Proactive Investors USA
Pharma & Biotech
Sustainability
Cannabis
Battery Metals
Artificial Intelligence
Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, The Canberra Times, and… Read more
Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is produced independently by our experienced and qualified teams of news journalists.
Proactive news team spans the world’s key finance and investing hubs with bureaus and studios in London, New York, Toronto, Vancouver, Sydney and Perth.
We are experts in medium and small-cap markets, we also keep our community up to date with blue-chip companies, commodities and broader investment stories. This is content that excites and engages motivated private investors.
The team delivers news and unique insights across the market including but not confined to: biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto and emerging digital and EV technologies.
Proactive has always been a forward looking and enthusiastic technology adopter.
Our human content creators are equipped with many decades of valuable expertise and experience. The team also has access to and use technologies to assist and enhance workflows.
Proactive will on occasion use automation and software tools, including generative AI. Nevertheless, all content published by Proactive is edited and authored by humans, in line with best practice in regard to content production and search engine optimisation.
Proactive Investors Australia Pty Ltd ACN 132 787 654 (the Company, we or us) provides you with access to the content set out above, including any news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) and this website (the Site) on the terms set out in this disclaimer, together with all other terms and conditions, disclaimers and other notices displayed elsewhere on this Site. It is important for you to know that: (a) none of the Content is, or is intended to be, general or personal advice (b) the principal purpose of the Content is to provide factual information only and to comment on news; (c) the Content does not contain or imply any recommendation or opinion intended to influence your financial decisions, including in respect of any particular security, portfolio of securities, transaction or…
Published: 11:53 16 Apr 2024 EDT
Semiconductor company ASML Holding NV (NASDAQ:ASML) is expected to report a year-over-year decline in both its profits and sales when it hands down its first quarter earnings on Wednesday, April 17.
Wall Street analysts, on average, see the Dutch chipmaker’s earnings per share decreasing by a whopping 46.3% to US$2.85 as sales are seen dropping more than 20% to US$5.73 billion.
The company itself has guided to Q1 sales in the range of €5.0 billion (US$5.34 billion) and €5.5 billion (US$5.84 billion), with gross margins between 48% and 49% compared to 50.6% in the year-ago quarter.
Back in January, the company said it expects 2024 to be a “transition year” as the semiconductor industry continues to work through the bottom of the cycle.
Shares of ASML traded hands at about $971.50 on Tuesday, having gained about 35% in the year to date.
Sign up to receive alerts and news direct to your inbox
BenevolentAI (OTC:BAIVF) Co-Founder Dr. Ivan Griffin shared exciting news with Proactive's Steve Darling regarding the company's collaboration with AstraZeneca. Through this partnership, AstraZeneca has incorporated a novel target for Heart Failure into its discovery portfolio, thanks to…
Copyright © Proactive Group Holdings Inc, 2024
All Rights Reserved – Proactive North America Inc., Proactive Investors LLC.
Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use.
